Tamoxifen treatment for breast cancer: Concept to gold standard

ONCOLOGY

Volumn 11, Issue 2 SUPPL. 1, 1997, Pages 7-13

  Craig Jordan, V ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Medical School   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE;

BREAST CANCER; CONFERENCE PAPER; DRUG EFFICACY; ENDOMETRIUM CANCER; FEMALE; HUMAN; RISK FACTOR;

ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; HISTORY, 20TH CENTURY; HUMANS; TAMOXIFEN;

EID: 0345354280     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
2. Henderson IC: Overviews of adjuvant tamoxifen therapy, in Jordan VC (ed): Tamoxifen, A Guide for Clinicians and Patients. pp 41 -63, New York, PRR, 1996.
3. Harper MJK, Walpole AL: Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature (London) 212:87, 1966.
4. Harper MJK, Walpole AL: A new derivative of triphenylethylene: Effect on implantation and mode of action in rats. J Reprod Fertil 13:101-119, 1967.
5. Jordan VC: The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L, Walpole. Breast Cancer Res Treat 11:197-209, 1988.
6. Cole MP, Jones MP, Todd DH. A new antiestrogenic agent in late breast cancer. An early appraisal of ICI 46,474. Br J Cancer 25:270-275, 1971.
7. Jordan VC: Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat Rep 60:1409-1419, 1976
8. Jordan VC: Antitumour activity of the antiestrogen ICI 46,474 (tamoxifen) in the dimethyl-benzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 5:354, 1974.
9. Jordan VC: Effect of tamoxifen (ICI 46,4741 on initiation and growth of DMBA-rat mammary carcinomata. Eur J Cancer 12:419-424, 1976.
10. Jordan VC: Tamoxifen and the prevention of breast cancer. Proc Soc Exp Biol Med 208:144-149, 1995.
11. Hubay CA, Peason OH, Marshall JS, et al: Adjuvant therapy of stage II breast cancer: 48 month folow-up of a prospective randomized clinical trial. Breast Cancer Res Treat 1:77-82, 1981.
12. Ribiero G, Palmer MK: Adjuvant tamoxifen for operable carcinoma of the breast' report of a clinical trial by the Christie Hospital and Holt Radium Institute Br Med J 286:827-830, 1983.
13. Ludwig Breast Cancer Study Group: Randomized trial of chemo-endocrine therapy and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastases. Lancet 1:1256-1260, 1985.
14. Rose C, Thorpe SM, Anderson KW, et al: Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1:16-19, 1985.
15. Jordan VC: Use of DMBA induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Rev Endo Related Cancer (October Suppl):49-55, 1978.
16. Jordan VC, Dix CJ, Allen KE: The effectiveness of long-term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer, in Salmon SE, Jones SE (eds): Adjuvant Therapy of Cancer III, pp 19-26. New York, Grune & Stratton, 1979.
17. Jordan VC, Allen KE: Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16:239-251, 1980.
18. Jordan VC: Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res Treat 3(suppl):73-86, 1983.
19. Nolvadex Adjuvant Trial Organization (NATO): Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Lancet 1:836-840, 1985.
20. Breast Cancer Trials Committee, Scottish Cancer Trials Office: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 2:171-175, 1987
21. Swedish Breast Cancer Co-Operative Group: Randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Instit 88:1543-1549, 1996.
22. Tormey DC, Jordan VC: Long-term tamoxifen adjuvant therapy in node positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat 4:297-302, 1984.
23. Tormey DC, Rasmussen P, Jordan VC: Update on long term tamoxifen study. Breast Cancer Res Treat 9:157-158, 1987.
24. Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205, 1984.
25. Jordan VC, Phelps E, Lindgren JU: Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10:31-35, 1987.
26. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992.
27. Bilimoria MM, Assikis VJ, Jordan VC: Should tamoxifen therapy be stopped at 5 years? Cancer J Sci Am 2:140-150, 1996.
28. Love RR, Weibe DA, Newcomb PA, et al: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women- Ann Intern Med 115:860-864, 1991.
29. Rutqvist LE, Mattson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage cancer in a randomized trial of adjuvant tamoxifen J Natl Cancer Inst 85:1398-1406, 1993.
30. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish tamoxifen trial. Br Med J 303:435-437, 1991.
31. McDonald CC, Alexander FE, Whyte BW, et al: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. Br Med J 311:977-980, 1995.
32. Satyaswaroop PC, Zaino RJ, Mortel R: Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 44:4006-4010, 1984.
33. Gottardis MM, Robinson SP, Satyaswaroop PG, et al: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48:812-815, 1988.
34. Horowitz RI, Feinstein AR: Estrogens and endometrial cancer: response to arguments and current status of an epidemiologic controversy. Am J Med 81:503-507, 1986.
35. Fornander T, Rutqvist LE, Cedermark B, et at: Adjuvant tamoxifen in early breast cancer, occurrence of new primary cancers. Lancet 1:117-120, 1989.
36. Assikis VJ, Jordan VC: Gynecological effects of tamoxifen and the association with endometrial cancer. Int J Gynecol Obstet 49:241-257, 1995.
37. Jordan VC, Assikis VJ: Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res 1:467-472, 1995.
38. Assikis VJ, Neven P, Jordan VC, et al: A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 32A:1464-1476, 1996.
39. Carmichael PL, Ugwumadu AHN, Neveu P, et al: Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 56:1475-1479, 1996.
40. Gottardis MM, Robinson SP, Jordan VC: Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 30:311-314, 1988.
41. Gottardis MM, Jordan VC: Development of tamoxifen stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187, 1988.
42. Legault-Poisson S, Jolivet J, Poisson R, et al: Tamoxifen-induced tumor stimulation and withdrawal reposnse. Cancer Treat Rep 63:1839-1841, 1979.
43. Canney PA, Griffiths T, Latief TN, et al: Clinical significance of tamoxifen withdrawal response [letter]. Lancet 1:36, 1987.
44. Howell A, Dodwell DJ, Anderson H, et al: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3:611-617, 1992.
45. Plourde PV, Dyroff M, Dukes M: Arimidex: A potent and selective fourth generation aromatase inhibitor Breast Cancer Res Treat 30:95-102, 1994.
46. Gradishar WJ, Jordan VC: The clinical potential of new antiestrogens. J Clin Oncol (in press).
47. Robinson SP, Mauel DA, Jordan VC: Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. Eur J Cancer Clin Oncol 24:1817-1821, 1988.
48. Hayes DF, Van Zyl JA, Hacking A, et al: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients in metastatic breast cancer. J Clin Oncol 13:2556-2566, 1995.
49. Wakeling AE: A new approach to breast cancer therapy - total estrogen ablation with pure antiestrogens, in Jordan VC (ed): Long-Term Tamoxifen Treatment for Breast Cancer, pp 219-234. Madison, University of Wisconsin Press, 1994.
50. Gottardis MM, Jiang SY, Jeng MH, et al: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49:4090-4093, 1989.
51. Howell A, DeFriend D, Robertson J, et al: Response to a specific antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet 345:29-30, 1995.